Tag: letter

PST Group AB hereby informs that on 4 July 2025 a letter regarding the intention to submit a tender offer, aimed at delisting the shares of PST Group AB from trading on AB Nasdaq Vilnius was received from the shareholder of the company AB “HISK” (please see the attached document).

TEL AVIV, Israel, July 03, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (“REE” or the “Company”) (Nasdaq: REE), an automotive technology company that develops software-defined vehicle (SDV) technology solutions, today reported that the Company received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is currently not in compliance with Nasdaq Rule 5450(a)(1). In particular, the Letter stated that the Company’s closing bid price for its Class A ordinary shares (the “Ordinary Shares”) has been below $1.00 per share for the last 30 consecutive business days beginning on May 15, 2025 through June 27, 2025.

EPSO-G (legal entity code 302826889, registered address Laisvės pr. 10, Vilnius, Lithuania)

MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has entered into a binding arrangement agreement with CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products, whereby the Purchaser will acquire all the issued and outstanding common shares of the Company for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”). The total Transaction consideration, assuming full payment of the CVRs, is US$254 million.

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized consumer rights law firm, is investigating potential claims against Ruffolo, Hooper & Associates, MD, PA (“Ruffolo, Hooper & Associates, MD, PA” or the “Company”) on behalf of Ruffolo, Hooper & Associates, MD, PA consumers. Our investigation concerns whether Ruffolo, Hooper & Associates, MD, PA has violated consumer protection laws and/or engaged in other unlawful business practices.